Johnson & Johnson (JNJ) to Issue Quarterly Dividend of $1.34 on June 9th

Johnson & Johnson (NYSE:JNJ) announced a quarterly dividend on Tuesday, April 14th. Investors of record on Tuesday, May 26th will be given a dividend of 1.34 per share on Tuesday, June 9th. This represents a c) dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Tuesday, May 26th. This is a 3.1% increase from Johnson & Johnson’s previous quarterly dividend of $1.30.

Johnson & Johnson has raised its dividend by an average of 0.1%annually over the last three years and has raised its dividend annually for the last 64 consecutive years. Johnson & Johnson has a payout ratio of 48.3% meaning its dividend is sufficiently covered by earnings. Research analysts expect Johnson & Johnson to earn $12.58 per share next year, which means the company should continue to be able to cover its $5.36 annual dividend with an expected future payout ratio of 42.6%.

Johnson & Johnson Price Performance

NYSE JNJ opened at $234.67 on Friday. The business has a 50 day simple moving average of $234.02 and a 200 day simple moving average of $223.28. Johnson & Johnson has a 52-week low of $149.04 and a 52-week high of $251.71. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The stock has a market cap of $564.91 billion, a price-to-earnings ratio of 27.13, a PEG ratio of 2.29 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same period in the prior year, the business earned $2.77 EPS. Johnson & Johnson’s revenue for the quarter was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Johnson & Johnson

Several large investors have recently made changes to their positions in JNJ. Brighton Jones LLC boosted its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the last quarter. United Bank boosted its holdings in shares of Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after buying an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after buying an additional 692 shares during the last quarter. Wealth Group Ltd. boosted its holdings in shares of Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock valued at $226,000 after buying an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. boosted its holdings in shares of Johnson & Johnson by 9.8% in the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock valued at $11,255,000 after buying an additional 6,584 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.